Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.56 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15850037 | 0.88 | MAPT (0.71) | LGMNMAPTALDH1A1PDK2MEN1 | |
| SCHEMBL3142718 | 0.87 | MAPT (0.70) | LGMNMAPTALDH1A1PDK2MEN1 | |
| SCHEMBL25845893 | 0.87 | LGMN (0.55) | LGMNMAPTALDH1A1SHMT2ITGB3 | |
| SCHEMBL18503028 | 0.86 | MAPT (0.65) | LGMNMAPTALDH1A1PDK2HPGD | |
| SCHEMBL17876417 | 0.86 | MAPT (0.65) | LGMNMAPTALDH1A1PDK2ITGB3 | |
| SCHEMBL14167547 | 0.86 | MAPT (0.68) | LGMNMAPTALDH1A1PDK2HPGD | |
| SCHEMBL1749330 | 0.86 | MAPT (0.68) | LGMNMAPTALDH1A1PDK2HPGD | |
| SCHEMBL17876413 | 0.86 | MAPT (0.68) | LGMNMAPTALDH1A1PDK2MEN1 | |
| SCHEMBL5913512 | 0.85 | MAPT (0.67) | LGMNMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL655166 | 0.85 | LGMN (0.70) | LGMNMAPTALDH1A1SHMT2PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20200079754-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2019-04-04 | — | — | US | disclosed |
| US-10052330-B2 | Substituted pyrido[3,4-b]pyrazines as Syk inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2018-08-21 | — | — | US | disclosed |
| US-10017478-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180155297-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-02-01 | — | — | US | disclosed |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2009029998-A1 | RETROMETABOLIC COMPOUNDS | CYTOPIA RESEARCH PTY LTD (AU) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009029998-A1 | RETROMETABOLIC COMPOUNDS | CYTOPIA RESEARCH PTY LTD (AU) | 2009-03-12 | — | — | WO | disclosed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070099934-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099934-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | LGMN 2623/4885MAPT 3561/4885ALDH1A1 573/4885 |
| US-20070099934-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | APOB, PNLIP, LIPC | LGMN 1502/4885MAPT 4151/4885ALDH1A1 909/4885 |
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | LGMN 2456/4885MAPT 4117/4885ALDH1A1 4745/4885 |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | LGMN 2623/4885MAPT 3561/4885ALDH1A1 573/4885 |
| US-10017478-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TNK2 | LGMN 2936/4885MAPT 4099/4885ALDH1A1 3704/4885 |
| US-20200079754-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | LGMN 2482/4885MAPT 4203/4885ALDH1A1 4726/4885 |
| US-20180155297-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | LGMN 2936/4885MAPT 4099/4885ALDH1A1 3704/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | LGMN 3691/4885MAPT 4734/4885ALDH1A1 1304/4885 |
| US-10052330-B2 | Substituted pyrido[3,4-b]pyrazines as Syk inhibitors | SYK, BTK, TYRO3 | LGMN 4682/4885MAPT 4026/4885ALDH1A1 3272/4885 |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | LGMN 2623/4885MAPT 3561/4885ALDH1A1 573/4885 |
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | LGMN 2519/4885MAPT 758/4885ALDH1A1 731/4885 |
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | LGMN 2485/4885MAPT 4086/4885ALDH1A1 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.